ERBB2 and breast cancer: Therapeutic strategies used for HER2-overexpressing breast cancers involve targeting the HER2 receptor and include the application monoclonal antibodies (e.g. trastuzumab) and tyrosine kinase inhibitors (e.g. lapatinib).